<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute cellulitis and erysipelas in adults: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute cellulitis and erysipelas in adults: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute cellulitis and erysipelas in adults: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larry M Baddour, MD, FIDSA, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Nelson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3649077324"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with skin and soft tissue infection may present with cellulitis, abscess, and other forms of infection [<a href="#rid1">1-3</a>].</p><p>This topic will discuss treatment of cellulitis and erysipelas. <span class="utd-adt-cnt utd-adt-pathwys utd-content-120460">(Related Pathway(s):  <a class="utd-content-120460" href="/pathway/120460?topicRef=110530&amp;source=see_link">Cellulitis and skin abscesses: Empiric antibiotic selection for adults</a>.)</span></p><p>Clinical manifestations and diagnosis of cellulitis and erysipelas are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p>Treatment of skin abscess is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/138447.html" rel="external">"Skin abscesses in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H924541965"><span class="h1">DIFFERENTIATING CELLULITIS FROM ERYSIPELAS</span><span class="headingEndMark"> — </span>Effective treatment of cellulitis and erysipelas depends on determining the most likely microorganism causing the infection. Beta-hemolytic streptococci cause most erysipelas infections and most cellulitis infections, but cellulitis is sometimes caused by <em>Staphylococcus aureus</em> and occasionally by a multitude of other organisms.</p><p>Examination and clinical features cannot always differentiate erysipelas from cellulitis, so we treat for cellulitis whenever we are uncertain. Both erysipelas and cellulitis manifest as areas of skin erythema, edema, and warmth. On physical examination, classic erysipelas presents as a bright red patch of skin with a clearly demarcated raised border  (<a class="graphic graphic_picture graphicRef82542" href="/z/d/graphic/82542.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef67112" href="/z/d/graphic/67112.html" rel="external">picture 2</a>). Cellulitis involves deeper layers of the skin, so it classically presents with indistinct borders that are not raised  (<a class="graphic graphic_picture graphicRef128910" href="/z/d/graphic/128910.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef128906" href="/z/d/graphic/128906.html" rel="external">picture 4</a>). </p><p>Details regarding the clinical presentation and diagnosis of erysipelas and cellulitis are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Cellulitis and erysipelas'</a>.)</p><p class="headingAnchor" id="H2126273051"><span class="h1">DETERMINING THE SITE OF CARE</span><span class="headingEndMark"> — </span>Cellulitis and erysipelas can both cause rapidly progressive and severe illness. Initial assessment of these infections should focus on determining the severity of illness and whether hospitalization is indicated.</p><p>Hospitalization is indicated for most individuals who warrant parenteral antibiotics and for all patients who are suspected to have high-risk "red-flag" conditions.</p><p class="headingAnchor" id="H1950972095"><span class="h2">"Red-flag" conditions that warrant hospitalization</span><span class="headingEndMark"> — </span>Red-flag conditions warrant immediate hospitalization, and some require urgent surgical intervention. Findings that increase suspicion for these conditions include severe sepsis or septic shock, rapidly progressive infection, or pain out of proportion to exam findings. Because of high morbidity and mortality, such conditions should be considered as part of the initial assessment of every individual with skin and soft tissue infection. Diagnosis and management of these conditions are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic shock syndrome</strong> – (See  <a class="medical medical_review" href="/z/d/html/3162.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3169.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Necrotizing soft tissue infection (eg, necrotizing fasciitis)</strong> – (See  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Joint involvement (with or without prosthesis)</strong> – (See  <a class="medical medical_review" href="/z/d/html/7666.html" rel="external">"Septic arthritis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Involvement of vascular graft</strong> – (See  <a class="medical medical_review" href="/z/d/html/120681.html" rel="external">"Overview of the evaluation and management of surgical site infection", section on 'Deep infection associated with implanted materials'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pyomyositis</strong> – (See  <a class="medical medical_review" href="/z/d/html/7669.html" rel="external">"Primary pyomyositis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clostridial myonecrosis (gas gangrene)</strong> – (See  <a class="medical medical_review" href="/z/d/html/7672.html" rel="external">"Clostridial myonecrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deep venous thrombosis (DVT)</strong> - (See  <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compartment syndrome</strong> – (See  <a class="medical medical_review" href="/z/d/html/358.html" rel="external">"Acute compartment syndrome of the extremities"</a> and  <a class="medical medical_review" href="/z/d/html/116596.html" rel="external">"Pathophysiology, classification, and causes of acute extremity compartment syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H961235367"><span class="h2">Indications for parenteral therapy</span><span class="headingEndMark"> — </span>The decision to initiate parenteral therapy is typically based on the extent and severity of infection and patient comorbidities. Patients who meet criteria for parenteral therapy are usually admitted to the hospital to ensure prompt administration and close observation.</p><p>For individuals with cellulitis or erysipelas without red-flag conditions, we suggest initial treatment with parenteral antibiotics in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic signs of toxicity such as fever &gt;100.5°F/38°C, hypotension, or sustained tachycardia (refractory hypotension should prompt consideration of toxic shock syndrome).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid progression of erythema (eg, doubling of the affected area within 24 hours; in particular, expansion over a few hours with severe pain should prompt consideration of necrotizing fasciitis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive erythema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-risk neutropenia [<a href="#rid4">4</a>]. Patients with neutropenia are classified as low- or high-risk based on scoring mechanisms that consider the anticipated duration of neutropenia, comorbidities, and severity of illness; such scoring systems are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes", section on 'Risk of serious complications'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to tolerate or absorb oral therapy</p><p></p><p>For patients with lymphangitis accompanying cellulitis, some UpToDate contributors would administer parenteral antibiotics because they believe that lymphangitis may be indicative of imminent bacteremia; there are minimal published data to support or refute this notion.</p><p>For immunocompromised patients with low-risk neutropenia or a non-neutropenic form of immunocompromise, we have a lower threshold for admission for IV antibiotics than we do for immunocompetent patients. Ultimately, clinical judgment is necessary and should consider the severity of infection, type of underlying immunocompromise, and ability for close follow-up in the outpatient setting. </p><p class="headingAnchor" id="H1695647194"><span class="h1">ACUTE CELLULITIS</span><span class="headingEndMark"> — </span>The pillars of cellulitis treatment are antibiotic therapy and management of exacerbating conditions, including the point of entry of infection. (See <a class="local">'Considerations prior to selecting antibiotics'</a> below and <a class="local">'Adjunctive treatments'</a> below.)</p><p class="headingAnchor" id="H864032073"><span class="h2">Considerations prior to selecting antibiotics</span><span class="headingEndMark"> — </span>At the time of presentation, selection of empiric antibiotic therapy is based on determining the most likely pathogen. In most cases, the causative pathogen is never identified. If a pathogen is identified, antibiotics should be narrowed to target the pathogen.</p><p>Factors that should be considered when choosing antibiotics for acute cellulitis include the severity and location of the cellulitis and whether coverage for methicillin-resistant <em>S. aureus</em> (MRSA) or atypical organisms is necessary. These issues are discussed in the sections that follow.</p><p class="headingAnchor" id="H1922604087"><span class="h3">Pathogens to always cover</span><span class="headingEndMark"> — </span>Empiric antibiotics for cellulitis should always cover beta-hemolytic streptococci and methicillin-sensitive <em>S. aureus </em>(MSSA), which are the two most common pathogens of cellulitis [<a href="#rid1">1-3</a>]. Further details regarding the microbiology of cellulitis are discussed elsewhere  (<a class="graphic graphic_table graphicRef143607" href="/z/d/graphic/143607.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Cellulitis and erysipelas'</a>.)</p><p class="headingAnchor" id="H2054037661"><span class="h3">Indications for MRSA coverage</span><span class="headingEndMark"> — </span>Empiric coverage for MRSA is indicated for patients with severe sepsis, certain MRSA risk factors, and those who have increased morbidity if suboptimal antibiotics are administered. Conditions that warrant MRSA coverage include the following [<a href="#rid2">2,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic signs of toxicity (eg, fever &gt;100.5°F/38°C, hypotension, sustained tachycardia)</p><p class="bulletIndent1"><span class="glyph">●</span>Cellulitis with purulent wound drainage</p><p class="bulletIndent1"><span class="glyph">●</span>Known MRSA colonization or infection </p><p class="bulletIndent1"><span class="glyph">●</span>Injection drug use</p><p class="bulletIndent1"><span class="glyph">●</span>High-risk neutropenia</p><p></p><p>Other risk factors may not be as strongly associated with MRSA infection, so we individualize the decision for MRSA coverage in such cases. For a complete list of risk factors for MRSA, refer to the table  (<a class="graphic graphic_table graphicRef53504" href="/z/d/graphic/53504.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H221796872"><span class="h3">Wounds and exposures that warrant specific coverage</span><span class="headingEndMark"> — </span>A broad range of organisms can cause cellulitis in individuals with wounds, injuries, or certain environmental exposures  (<a class="graphic graphic_table graphicRef143607" href="/z/d/graphic/143607.html" rel="external">table 1</a>). Antibiotic regimens for these conditions are distinct and discussed in detail elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wounds and injuries</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diabetic foot ulcers – (See  <a class="medical medical_review" href="/z/d/html/7651.html" rel="external">"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Animal bites – (See  <a class="medical medical_review" href="/z/d/html/7671.html" rel="external">"Animal bites (dogs, cats, and other mammals): Evaluation and management", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Human bites – (See  <a class="medical medical_review" href="/z/d/html/7674.html" rel="external">"Human bites: Evaluation and management", section on 'Infected bites'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Puncture wounds other than bites – (See  <a class="medical medical_review" href="/z/d/html/7661.html" rel="external">"Infectious complications of puncture wounds"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pressure injury or pressure ulcer – (See  <a class="medical medical_review" href="/z/d/html/7657.html" rel="external">"Infectious complications of pressure-induced skin and soft tissue injury"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical wound – (See  <a class="medical medical_review" href="/z/d/html/120681.html" rel="external">"Overview of the evaluation and management of surgical site infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environmental exposures</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Water exposure – (See  <a class="medical medical_review" href="/z/d/html/7646.html" rel="external">"Soft tissue infections following water exposure"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Soil exposure - (See  <a class="medical medical_review" href="/z/d/html/7661.html" rel="external">"Infectious complications of puncture wounds"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Travel-related skin infections – (See  <a class="medical medical_review" href="/z/d/html/3895.html" rel="external">"Skin lesions in the returning traveler"</a> and  <a class="medical medical_review" href="/z/d/html/3146.html" rel="external">"Melioidosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Skin infection'</a>.)</p><p></p><p class="headingAnchor" id="H4194474824"><span class="h3">Anatomic site of infection</span><span class="headingEndMark"> — </span>Cellulitis can occur on any part of the body. Depending on the location of cellulitis, antibiotic selection and other interventions, including surgery, can vary.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellulitis of the extremities</strong> – The extremities are the most common site of cellulitis. In the absence of a red-flag condition or other indication for broadened antibiotic coverage, treatment focuses on beta-hemolytic streptococci and <em>S. aureus</em>.<em> </em>(See <a class="local">'"Red-flag" conditions that warrant hospitalization'</a> above and <a class="local">'Selecting an antibiotic regimen'</a> below.)</p><p></p><p class="bulletIndent1">If cellulitis involves the hand, hospitalization is typically recommended along with evaluation by a surgeon. Management of hand infections is discussed in depth elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15117.html" rel="external">"Overview of hand infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Facial cellulitis</strong> – Facial skin infections are more often due to erysipelas than cellulitis. Treatment of facial cellulitis focuses on beta-hemolytic streptococci and <em>S. aureus</em>. (See <a class="local">'Selecting an antibiotic regimen'</a> below.)</p><p></p><p class="bulletIndent1">If the area around the eye is cellulitic, differentiation of preseptal (periorbital) from orbital cellulitis is paramount. Preseptal cellulitis is generally a mild infection of the skin around the eye, whereas orbital cellulitis involves the deeper tissues of the eye and can lead to loss of vision or even loss of life. Rarely, infections involving the medial third of the face (ie, the areas around the eyes and nose) can be complicated by septic cavernous thrombosis, a life-threatening disease. More details regarding diagnosis and management of preseptal and orbital cellulitis, as well as septic cavernous thrombosis, are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16650.html" rel="external">"Preseptal cellulitis"</a> and  <a class="medical medical_review" href="/z/d/html/3414.html" rel="external">"Orbital cellulitis"</a> and  <a class="medical medical_review" href="/z/d/html/3410.html" rel="external">"Septic dural sinus thrombosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neck cellulitis</strong> – Cellulitis of the neck is uncommon. When present, consideration should be given to underlying deep neck space infection or submandibular space infection (Ludwig angina), both of which require urgent evaluation and management. Diagnosis and management of deep neck space infections are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3415.html" rel="external">"Deep neck space infections in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13964.html" rel="external">"Ludwig angina"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cellulitis</strong> – Breast cellulitis is usually due to beta-hemolytic streptococci or <em>S. aureus</em> and is managed similarly to uncomplicated cellulitis, as described below (see <a class="local">'Selecting an antibiotic regimen'</a> below). Additional considerations regarding the management of breast cellulitis are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/797.html" rel="external">"Breast cellulitis and other skin disorders of the breast", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellulitis of the abdominal wall</strong> – Most reports of abdominal-wall cellulitis of adults are in individuals with surgical site infection, abdominal-wall mesh infection, or intra-abdominal conditions such as appendicitis or colon cancer. In each of these situations, both surgical intervention and antibiotic therapy are usually necessary for management [<a href="#rid6">6-17</a>]. Management of these conditions is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/120681.html" rel="external">"Overview of the evaluation and management of surgical site infection"</a> and  <a class="medical medical_review" href="/z/d/html/15100.html" rel="external">"Wound infection following repair of abdominal wall hernia"</a>.)</p><p></p><p class="bulletIndent1">Few reports of idiopathic abdominal-wall cellulitis exist, but the infection is probably more common than the medical literature suggests. In a case series of 260 patients with cellulitis and morbid obesity between 1998 and 2003, 24 (9 percent) had idiopathic abdominal-wall cellulitis [<a href="#rid18">18</a>]. Of those 24 patients, 17 (71 percent) had a remote history of healed abdominal surgery, 10 (42 percent) had diabetes mellitus, 7 (29 percent) experienced recurrences, and 3 (13 percent) underwent surgical debridement and/or panniculectomy. Eleven (46 percent) had an underlying dermatologic condition of the abdominal wall, most commonly lymphedema and/or intertrigo.</p><p></p><p class="bulletIndent1">No studies have evaluated treatment of idiopathic abdominal-wall cellulitis. We use the same approach as for cellulitis in general. (See <a class="local">'Selecting an antibiotic regimen'</a> below.)</p><p></p><p class="bulletIndent1">We suggest treating underlying dermatologic and other contributing conditions, such as intertrigo, while the patient is receiving antimicrobial therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellulitis of the perineum or genitalia</strong> – Skin infections of the perineum and genitals can be due to cellulitis, folliculitis, or other etiologies. Of most concern is Fournier gangrene, a polymicrobial necrotizing fasciitis of the perineum that can involve the lower abdominal wall, the penis and scrotum in men, and the labia in women. Fournier gangrene is a medical and surgical emergency with a high fatality rate. Details regarding diagnosis and management of Fournier gangrene are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a>.)</p><p></p><p class="headingAnchor" id="H770209968"><span class="h2">Selecting an antibiotic regimen</span><span class="headingEndMark"> — </span>The first step when selecting an initial antibiotic regimen for cellulitis is to determine whether providing coverage beyond beta-hemolytic streptococci and <em>S. aureus</em> is necessary. Certain conditions, exposures, or anatomic sites often require broader antibiotic coverage than standard regimens, and antibiotic selection for those conditions is discussed elsewhere  (<a class="graphic graphic_table graphicRef143607" href="/z/d/graphic/143607.html" rel="external">table 1</a>). (See <a class="local">'"Red-flag" conditions that warrant hospitalization'</a> above and <a class="local">'Considerations prior to selecting antibiotics'</a> above.)</p><p>For most patients with cellulitis who don't have features that warrant specific management, our approach depends on the severity of illness, patient's immune status, and risk for MRSA, as outlined below and in the algorithm  (<a class="graphic graphic_algorithm graphicRef139109" data-inline-graphics="139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>). <span class="utd-adt-cnt utd-adt-pathwys utd-content-120460">(Related Pathway(s):  <a class="utd-content-120460" href="/pathway/120460?topicRef=110530&amp;source=see_link">Cellulitis and skin abscesses: Empiric antibiotic selection for adults</a>.)</span></p><p>In general, our antibiotic recommendations match those of expert guidelines [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H789331130"><span class="h3">Patients with severe sepsis</span><span class="headingEndMark"> — </span>In the setting of severe sepsis, rapid administration of empiric broad-spectrum antibiotics is indicated because delay or lack of adequate coverage increases mortality [<a href="#rid19">19,20</a>]. Of note, patients with septic shock, manifest by refractory hypotension, may have toxic shock syndrome or another red-flag condition and should be managed accordingly, as discussed elsewhere. (See <a class="local">'"Red-flag" conditions that warrant hospitalization'</a> above.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – We suggest the following antibiotic regimen for patients with severe sepsis  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (see table for dosing  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 3</a>))</p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">Cefepime</a> 2 g intravenously (IV) every eight hours</p><p></p><p class="bulletIndent1">Other regimens may be more appropriate in certain situations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are known or suspected of having an infection due to an organism with an extended-spectrum beta-lactamase (ESBL), we suggest using an empiric carbapenem (eg, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> 1 g IV every eight hours) in conjunction with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with reported beta-lactam allergies, empiric antibiotic selection depends on the type and severity of the reaction  (<a class="graphic graphic_algorithm graphicRef112936" href="/z/d/graphic/112936.html" rel="external">algorithm 2</a>). Patients with mild, non-immunoglobulin (Ig)E-mediated reactions to penicillins (eg, maculopapular rash) can usually safely receive cephalosporins; carbapenems are typically safe in patients who cannot take penicillins or cephalosporins (see  <a class="medical medical_review" href="/z/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a>). For patients who cannot take any beta-lactam agent, we suggest intravenous <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 3</a>) paired with either <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> (750 mg IV once daily) or <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> (2 g IV every eight hours; dosing up to 2 g every six hours may be reasonable for weight &gt;120 kg). Note that individuals with a history of life-threatening or anaphylactic reaction to <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> should not be given aztreonam, but levofloxacin is generally safe.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral step-down therapy</strong> – Once clinical improvement and resolution of sepsis occur, it is generally appropriate to transition to an oral regimen. If a pathogen is identified during the course of therapy, antibiotics should be narrowed to coverage specific for that pathogen.</p><p></p><p class="bulletIndent1">If a pathogen is not identified, stable patients who are not immunocompromised can generally be transitioned to one of the narrower oral agents described below. (See <a class="local">'Immunocompetent patients without severe sepsis'</a> below.)</p><p></p><p>The rationale for using a spectrum that covers pathogens in addition to streptococci and <em>S. aureus</em> is the risk of poor outcomes with a narrower spectrum of empiric therapy in severely ill patients if other pathogens are involved. </p><p class="headingAnchor" id="H689265319"><span class="h3">Immunocompetent patients without severe sepsis</span><span class="headingEndMark"> — </span>We typically divide this group of patients into those who warrant MRSA coverage and those who do not  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>). Indications for MRSA coverage are described above. (See <a class="local">'Indications for MRSA coverage'</a> above.)</p><p class="headingAnchor" id="H1105384143"><span class="h4">Without an indication for MRSA coverage</span><span class="headingEndMark"> — </span>For most patients, antibiotic regimens that cover beta-hemolytic streptococci and MSSA<em> </em>are effective, and coverage for MRSA is not necessary [<a href="#rid2">2,5,21,22</a>]. We suggest one of the following regimens  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antibiotic regimens</strong> – Many patients with cellulitis of the lower extremity can be managed with oral antibiotics in the outpatient setting [<a href="#rid23">23</a>]. For such patients, we suggest one of the following regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">Dicloxacillin</a> 500 mg orally every six hours</p><p class="bulletIndent2"><span class="glyph">•</span>Flucloxacillin 500 to 1000 mg orally every six hours (not available in the United States)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">Cephalexin</a> 500 mg orally every six hours</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">Cefadroxil</a> 500 mg orally every 12 hours or 1 g orally once daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral antibiotic regimens</strong> – Parenteral antibiotics are recommended for higher risk patients (see <a class="local">'Indications for parenteral therapy'</a> above). For such patients, we suggest one of the following regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">Cefazolin</a> 1 to 2 g IV every eight hours</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">Nafcillin</a> 1 to 2 g IV every four hours</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">Oxacillin</a> 1 to 2 g IV every four hours</p><p class="bulletIndent2"><span class="glyph">•</span>Flucloxacillin 2 g IV every six hours (not available in the United States)</p><p></p><p class="bulletIndent1">For <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>, and <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, we usually favor the higher dosages listed above (ie, 2 g) for treatment of these infections.</p><p></p><p class="bulletIndent1">Once there is evidence of clinical improvement, parenteral antibiotics should be switched to one of the oral regimens listed above [<a href="#rid24">24</a>].</p><p></p><p>Studies suggest that most patients with cellulitis do not need MRSA coverage:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial of adults with nonpurulent cellulitis in five emergency departments in the United States noted similar clinical cure rates among those treated with <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> plus TMP-SMX and those treated with cephalexin plus placebo [<a href="#rid21">21</a>]. In the per-protocol analysis, 182 (84 percent) of 218 individuals in the cephalexin plus TMP-SMX group achieved cure versus 165 (86 percent) of 193 in the cephalexin group (difference -2 percent; 95% CI, -9.7 to 5.7 percent). The modified intention-to-treat analysis suggested a possible trend favoring the cephalexin plus TMP-SMX group, but those results are difficult to interpret due to a large number of patients in both groups who did not complete the full course of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another randomized trial of 153 patients with cellulitis without abscess noted comparable cure rates among those treated with <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> and TMP-SMX (85 percent) and those treated with cephalexin and placebo (82 percent; difference 2.7 percent, 95% CI -9.3 to 15 percent) [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H878284458"><span class="h4">With an indication for MRSA coverage</span><span class="headingEndMark"> — </span>MRSA coverage is indicated if certain conditions are present (see <a class="local">'Indications for MRSA coverage'</a> above). We suggest one of the following regimens  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antibiotic regimens</strong> – For many patients, treatment in the outpatient setting with oral antibiotics is effective [<a href="#rid23">23</a>]. We suggest one of the following regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TMP-SMX (one to two double-strength tablets orally twice daily; for patients who weigh more than 70 kg and have normal renal function, we favor two double-strength tablets twice daily).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">Amoxicillin</a> (875 mg orally twice daily) plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily).</p><p></p><p class="bulletIndent1">TMP-SMX has activity against both <em>Streptococcus</em> and <em>S. aureus</em>, including MRSA. <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> provides coverage for <em>S. aureus</em>, including MRSA; <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> is added to it for streptococcal coverage. Cellulitis cure rates with TMP-SMX range from 78 to 83 percent [<a href="#rid25">25,26</a>], and support for doxycycline is based on observational data, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections", section on 'Oral antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> (600 mg orally every 12 hours) is acceptable if the above agents cannot be used. Meta-analyses, systematic reviews, and randomized trials suggest that linezolid has at least equivalent outcomes for skin and soft tissue infections (including MRSA infections) when compared with intravenous <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid27">27-30</a>]. The analyses also found elevated rates of nausea, vomiting, and thrombocytopenia when linezolid was administered; we suggest weekly complete blood counts for patients receiving linezolid for longer than two weeks. Linezolid is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections", section on 'Linezolid and tedizolid'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> (450 mg orally every eight hours) may have activity against both <em>Streptococcus</em> and <em>S. aureus</em> and is an alternative if no other options exist; we avoid its use due to risk for <em>Clostridioides difficile</em> infection and the possibility of streptococcal and staphylococcal resistance. Local rates of resistance to clindamycin should be considered before prescribing, as described below. (See <a class="local">'Alternatives for serious beta-lactam allergy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral antibiotic regimen</strong> – For patients who meet criteria for parenteral antibiotics, we suggest the following regimen (see <a class="local">'Indications for parenteral therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (see table for dosing  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 3</a>)) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> 4 to 6 mg/kg IV every 24 hours (alternative)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> is the preferred option because of extensive experience with this agent. When <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> is used, we usually favor the higher dose (ie, 6 mg/kg). For patients who cannot take vancomycin or daptomycin, alternative agents can be used and are listed in the table  (<a class="graphic graphic_table graphicRef110072" href="/z/d/graphic/110072.html" rel="external">table 4</a>), and their efficacy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.)</p><p></p><p class="bulletIndent1">Once there is evidence of clinical improvement, parenteral antibiotics should be switched to one of the oral regimens listed above.</p><p></p><p class="headingAnchor" id="H315774106"><span class="h4">Alternatives for serious beta-lactam allergy</span><span class="headingEndMark"> — </span>Although many patients have reported beta-lactam allergies, most do not have allergies that would prohibit the use of beta-lactams. In particular, many with penicillin allergies can still take a cephalosporin  (<a class="graphic graphic_algorithm graphicRef112936" href="/z/d/graphic/112936.html" rel="external">algorithm 2</a>). Evaluation and management of reported penicillin allergies are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a> and  <a class="medical medical_review" href="/z/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p class="bulletIndent1">For immunocompetent patients without severe sepsis who have serious allergies that preclude use of beta-lactams, we suggest one of the following regimens  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antibiotic regimen</strong> – If no indication for parenteral antibiotics is present, we suggest either of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TMP-SMX (one to two double-strength tablets orally twice daily).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> (600 mg orally every 12 hours). More detail regarding this agent is discussed above. (See <a class="local">'With an indication for MRSA coverage'</a> above.)</p><p></p><p class="bulletIndent1">An alternative is <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (450 mg orally every eight hours), but we generally avoid it due to risk <em>of C. difficile</em> infection and the possibility of streptococcal and staphylococcal resistance [<a href="#rid25">25,31</a>]. Local rates of resistance to clindamycin should be considered before prescribing. Data from the United States Centers for Disease Control and Prevention (CDC) found that 22 percent of group<em> </em>A<em> Streptococcus</em> isolates and 47 percent of MRSA isolates were resistant to clindamycin in 2017 [<a href="#rid32">32,33</a>]. In Australia in 2019, clindamycin resistance was reported in 7 percent of group A <em>Streptococcus</em> and 30 percent of MRSA isolates [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">Data suggest that TMP-SMX and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> are equally effective for management of cellulitis. In one randomized trial of outpatients with cellulitis, 110 (81 percent) of 136 individuals who received clindamycin achieved cure versus 110 (76 percent) of 144 who received TMP-SMX (difference -4.5 percent; 95% CI, -15.1 to 6.1 percent) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">We do not recommend macrolides, such as <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, due to high resistance rates among beta-hemolytic streptococci [<a href="#rid2">2,32,35</a>]. The CDC reported that 23 percent of group A streptococci were resistant to macrolides in 2017 [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral antibiotic regimen</strong> – For patients with an indication for parenteral therapy, we suggest intravenous <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 3</a>). (See <a class="local">'Indications for parenteral therapy'</a> above.)</p><p></p><p class="bulletIndent1">For patients who cannot take <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, alternative parenteral agents can be used and are listed in the table  (<a class="graphic graphic_table graphicRef110072" href="/z/d/graphic/110072.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">Once there is evidence of clinical improvement, parenteral antibiotics should be switched to one of the oral regimens listed above.</p><p></p><p class="headingAnchor" id="H2011644580"><span class="h3">Immunocompromised patients without severe sepsis</span><span class="headingEndMark"> — </span>Patients who have certain immunocompromising conditions are at risk for a wide range of pathogens. However, there is a spectrum of immunocompromising conditions, and some do not substantially increase risk. Ultimately, choosing an antibiotic regimen for immunocompromised patients should depend on the type of underlying immunocompromise, severity of infection, and ability for close follow-up in the outpatient setting.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with high-risk neutropenia</strong> – We hospitalize these patients for prompt administration of intravenous broad-spectrum antibiotics that cover gram-negative pathogens (including <em>Pseudomonas</em> spp) in addition to streptococci and<em> S. aureus</em>. Our preferred regimen is <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>  (<a class="graphic graphic_table graphicRef67027" href="/z/d/graphic/67027.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Initial regimen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with immunocompromise other than high-risk neutropenia</strong> – In our experience, many patients in this group can be treated with IV or oral therapy using the same regimens as the immunocompetent population. (See <a class="local">'Immunocompetent patients without severe sepsis'</a> above and <a class="local">'Indications for parenteral therapy'</a> above.)</p><p></p><p class="bulletIndent1">Some immunocompromising conditions can be associated with specific pathogens  (<a class="graphic graphic_table graphicRef143607" href="/z/d/graphic/143607.html" rel="external">table 1</a>). For example, patients with cirrhosis can develop cellulitis from enteric gram-negative bacilli (eg,<em> Klebsiella </em>spp), so some experts select a regimen that covers those organisms (eg, <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>). As another example, patients with low-risk neutropenia are at risk for pseudomonal infection, so many experts administer combination therapy (eg, amoxicillin-clavulanate plus <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>). </p><p></p><p class="bulletIndent1">Ultimately, the decision to broaden coverage beyond beta-hemolytic streptococci and <em>S. aureus </em>is nuanced and requires clinical judgment. </p><p></p><p class="headingAnchor" id="H3868927574"><span class="h2">Duration of antibiotic therapy</span><span class="headingEndMark"> — </span>The duration of therapy should be individualized depending on clinical response. In general, five to six days of therapy is appropriate for patients with uncomplicated cellulitis whose infection has improved [<a href="#rid2">2,36,37</a>]. Extension of antibiotic therapy (up to 14 days) may be warranted in the setting of severe infection, slow response to therapy, or immunocompromise.</p><p>The above suggested duration is supported by a meta-analysis of eight randomized controlled trials totaling almost 1500 adults with cellulitis that found no difference in response rates between short (five to six days) and longer courses of antibiotics (relative risk [RR] 0.99, 95% CI 0.96-1.03) [<a href="#rid23">23</a>]. The only trial that assessed outcome beyond 30 days was a trial of 151 individuals hospitalized with nonpurulent cellulitis who were randomized to treatment with a 6-day or 12-day course of flucloxacillin [<a href="#rid38">38</a>]. Cure rates were similar between the groups (74 versus 67 percent); relapse rates after 90 days were higher in the 6-day group (6 versus 24 percent), but most relapses in the 6-day group were in patients with a history of at least one prior episode of cellulitis.</p><p class="headingAnchor" id="H1314915164"><span class="h2">Adjunctive treatments</span><span class="headingEndMark"> — </span>When treating cellulitis of the lower extremities, management of exacerbating conditions and any points of entry for microorganisms is paramount.</p><p class="headingAnchor" id="H3400842471"><span class="h3">Elevation and edema management</span><span class="headingEndMark"> — </span>Edema, a common manifestation of cellulitis, can impair antibiotic penetration into infected tissue and prevent resolution of infection. For lower extremity cellulitis, elevation of the affected limb hastens improvement by allowing gravity drainage of edema and inflammatory substances [<a href="#rid2">2</a>]. To optimize the effect of gravity, we instruct patients to elevate the heel of the foot above the knee and the knee above the hip.</p><p>Lymphedema and venous insufficiency are commonly associated with lower extremity cellulitis, especially in individuals who are obese. In addition to elevation, compression therapy can be used to treat both lymphedema and venous insufficiency. While compression therapy has been shown to be effective for preventing recurrences of cellulitis in individuals with lymphedema, the efficacy of compression therapy during acute cellulitis is uncertain, and clinical practice varies, including among UpToDate contributors. Traditionally, compression therapy was felt to be contraindicated during episodes of acute cellulitis for fear of compromising vascular function, although no data support this contraindication. Limited data suggest that individualized compression therapy applied by specialized lymphedema physiotherapists may not be harmful and does not compromise microcirculation in patients with active cellulitis [<a href="#rid39">39,40</a>]. Compression therapy should be avoided in individuals with known or suspected arterial insufficiency. Details regarding the management of lymphedema and venous insufficiency are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/17013.html" rel="external">"Lower extremity lymphedema"</a> and  <a class="medical medical_review" href="/z/d/html/738.html" rel="external">"Clinical staging and conservative management of peripheral lymphedema"</a> and  <a class="medical medical_review" href="/z/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease"</a> and  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency"</a>.)</p><p class="headingAnchor" id="H1360699377"><span class="h3">Skin management</span><span class="headingEndMark"> — </span>Treatment of skin conditions and the point of microorganism entry can expedite resolution of cellulitis.</p><p>The point of entry of microorganisms should be identified and managed at the time of diagnosis of cellulitis. Common points of entry include intertrigo in the toe webs of the feet, tinea pedis, onychomycosis, and lower extremity ulcers. Details regarding diagnosis and management of these issues are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/115366.html" rel="external">"Intertrigo"</a> and  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Tinea pedis'</a> and  <a class="medical medical_review" href="/z/d/html/105222.html" rel="external">"Onychomycosis: Management"</a> and  <a class="medical medical_review" href="/z/d/html/13680.html" rel="external">"Approach to the differential diagnosis of leg ulcers"</a>.)</p><p>As cellulitis evolves, skin can begin to weep, blister, flake, or crack. Dermatologists and wound care specialists can provide assistance with management of these conditions. More details regarding the cutaneous progression of cellulitis are found below. (See <a class="local">'Monitoring response to therapy'</a> below.)</p><p>Numerous underlying skin conditions are risk factors for the development of cellulitis including atopic dermatitis (eczema) and psoriasis. Such conditions should be optimally managed in conjunction with standard cellulitis treatment. Details regarding skin conditions that predispose to cellulitis are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H3615772706"><span class="h3">Interventions that are not recommended</span><span class="headingEndMark"> — </span>We do not recommend the following therapies. These recommendations generally match those of expert guidelines [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-inflammatory medications</strong> – We suggest not using nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids when there is concern for moderate to severe cellulitis. These drugs can mask signs and symptoms of inflammation in patients with necrotizing soft tissue infection, and their use may be associated with delay in diagnosis. </p><p></p><p class="bulletIndent1">For patients with mild infection, anti-inflammatory medications may reduce symptoms of pain. While some data suggest that use of NSAIDs or corticosteroids may hasten healing among patients with cellulitis or erysipelas, these results are inconclusive and are limited by small sample size [<a href="#rid41">41-43</a>]. (See  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical antibiotics</strong> – Although topical antibiotics are effective for some skin infections (eg, impetigo, folliculitis), topical antibiotics are unlikely to be effective for cellulitis or erysipelas due to involvement of the layers of skin below the epidermis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperbaric oxygen therapy</strong> – For cellulitis, hyperbaric oxygen therapy has not been shown to be effective [<a href="#rid2">2</a>]. Further information on hyperbaric oxygen therapy is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/326.html" rel="external">"Hyperbaric oxygen therapy"</a>.)</p><p></p><p class="headingAnchor" id="H987365699"><span class="h1">TREATMENT OF ERYSIPELAS</span><span class="headingEndMark"> — </span>Management of erysipelas primarily consists of antibiotic therapy along with the adjunctive therapies described above. (See <a class="local">'Adjunctive treatments'</a> above.)</p><p class="headingAnchor" id="H4271015087"><span class="h2">Oral antibiotics for erysipelas</span><span class="headingEndMark"> — </span>Most cases of erysipelas can be managed with oral antibiotics in the outpatient setting. For patients with unambiguous erysipelas who do not meet criteria for parenteral antibiotics, empiric oral antibiotics active against beta-hemolytic streptococci should be administered (see <a class="local">'Indications for parenteral therapy'</a> above). We suggest one of the following regimens:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">Penicillin V</a> potassium 500 mg orally every six hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">Amoxicillin</a> 875 mg orally every 12 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">Cephalexin</a> 500 mg orally every six hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">Cefadroxil</a> 500 mg orally every 12 hours or 1 g orally once daily</p><p></p><p>For patients with serious beta-lactam allergies that preclude use of the above regimens, oral options are the same as those listed above for cellulitis. (See <a class="local">'Alternatives for serious beta-lactam allergy'</a> above.)</p><p class="headingAnchor" id="H203760868"><span class="h2">Parenteral antibiotics for erysipelas</span><span class="headingEndMark"> — </span>We suggest antibiotics that cover beta-hemolytic streptococci and <em>S. aureus </em>for patients with erysipelas who have an indication for parenteral therapy (see <a class="local">'Indications for parenteral therapy'</a> above). Differentiating erysipelas from cellulitis is not always straightforward, so we believe that adding staphylococcal coverage is prudent in individuals who are ill enough to warrant parenteral therapy.</p><p>For such patients, appropriate regimens include those described in the above discussion about antibiotic therapy for cellulitis. </p><p>If a microbiologic diagnosis of beta-hemolytic <em>Streptococcus</em> is subsequently established (eg, by a positive blood culture), then we recommend switching to parenteral aqueous crystalline <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> (2 to 4 million units intravenously [IV] every four to six hours).</p><p>For patients in whom outpatient parenteral antibiotic is desired, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 to 2 g IV once daily) is an alternative that allows for convenient once-daily outpatient administration.</p><p>Once there is evidence of clinical improvement, parenteral antibiotics should be switched to oral antibiotics that cover streptococci. Appropriate oral antibiotics for erysipelas are described above. (See <a class="local">'Oral antibiotics for erysipelas'</a> above.)</p><p class="headingAnchor" id="H558134257"><span class="h2">Duration of antibiotic therapy</span><span class="headingEndMark"> — </span>In general, the duration of therapy for erysipelas is analogous to the duration used for cellulitis. (See <a class="local">'Duration of antibiotic therapy'</a> above.)</p><p class="headingAnchor" id="H2197959716"><span class="h1">MONITORING RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>Patients with cellulitis or erysipelas typically have symptomatic improvement within 24 to 48 hours of beginning antimicrobial therapy, although visible improvement of skin manifestations can take 72 hours or longer [<a href="#rid44">44,45</a>]. In some cases, we monitor patients remotely by having patients send daily pictures of their infection to our clinic; we advise patients to take photographs from the same angle and in the same environment, with particular attention to lighting.</p><p>It is useful to document the baseline appearance of the physical findings at the start of antibiotic therapy. We obtain a baseline digital photograph to help monitor progress. Some experts outline the area of infection with an indelible marker at the time of treatment initiation to allow objective monitoring of progress. Other do not outline the infection because patients sometimes experience unnecessary anxiety if the infection appears to extend beyond the line as the infection dissipates. In the early stages of treatment, erythema may expand beyond the initial margins of infection as the infection dissipates. Deepening of erythema may be observed due to destruction of pathogens that can enhance local inflammation. These findings should not be mistaken for therapeutic failure. Clues that the infection is improving include reductions in fever, pain, brightness or intensity of erythema, peripheral white blood cell count, and other signs of infection.</p><p>As cellulitis evolves, skin can begin to weep, blister, flake, or crack. None of these findings are necessarily indications of worsening infection. As discussed elsewhere, wound care specialists or dermatologists can help to manage these conditions. (See <a class="local">'Skin management'</a> above.)</p><p>Residual skin inflammation is a common finding after completion of effective therapy [<a href="#rid38">38,44</a>]. In a study of 216 patients hospitalized for cellulitis, more than half had residual inflammation at the end of therapy [<a href="#rid45">45</a>]. Per telephone consultation done approximately two weeks after completion of therapy, approximately 40 percent still had residual inflammation and 16 percent had deterioration or required readmission.</p><p class="headingAnchor" id="H2054801549"><span class="h1">REFRACTORY INFECTION</span><span class="headingEndMark"> — </span>Significant progression of erythema or persistence of systemic symptoms after 24 to 48 hours should prompt a search for possible reasons for treatment failure. Evaluation should consider multiple possibilities:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Red-flag condition</strong> – Any time cellulitis progresses rapidly or clinical symptoms, especially pain, seem to be out of proportion to physical exam, red-flag conditions should be considered. A low threshold for surgical consultation to evaluate for these conditions is prudent. A list of red-flag conditions is provided above. (See <a class="local">'"Red-flag" conditions that warrant hospitalization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate dosing or tissue penetration of antibiotics</strong> – Conditions at the site of infection, such as edema or peripheral artery disease, can markedly reduce the ability of antibiotics to penetrate into soft tissue. To optimize tissue penetration of the antibiotics, management of these conditions is paramount. (See <a class="local">'Adjunctive treatments'</a> above.)</p><p></p><p class="bulletIndent1">In patients failing oral antibiotics, switching from oral to intravenous antibiotics can markedly increase antibiotic delivery to the site of infection. This is especially the case for antibiotics with poor bioavailability (such as some beta-lactam agents) or for patients whose ability to absorb oral medications is uncertain.</p><p></p><p class="bulletIndent1">In select situations, using higher antibiotic dosages may be beneficial. Obesity can increase drug clearance from circulation and thereby limit the amount of antibiotic that reaches the site of infection [<a href="#rid46">46</a>]. Moreover, certain bacteria, such as <em>Pseudomonas</em> spp, require higher antibiotic dosages to achieve bacterial killing. Consultation with a pharmacist may be helpful in these cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abscess</strong> – As cellulitis responds to antibiotic therapy, sometimes the infection can coalesce to form an abscess below the surface. Abscess should be suspected when focal tender fluctuance is found on exam, and ultrasound can aid in detection. If present, surgical consultation for incision and drainage is recommended. Detailed discussion of skin abscess management is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/138447.html" rel="external">"Skin abscesses in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis other than cellulitis or erysipelas</strong> – Failure to respond to appropriate therapy should prompt consideration that the initial diagnosis of cellulitis is incorrect. Cellulitis is often confused with other infectious and noninfectious illnesses, and misdiagnosis is perhaps the most common cause of lack of response to therapy [<a href="#rid47">47,48</a>]. The differential diagnosis of cellulitis and erysipelas is broad and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Cellulitis and erysipelas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistant pathogen</strong> – Re-evaluating for the possibility of resistant microorganisms and reviewing past culture data can help guide antibiotic change. Methicillin-resistant <em>S. aureus </em>(MRSA) or other organisms associated with certain conditions or environmental exposures should be considered. (See <a class="local">'Considerations prior to selecting antibiotics'</a> above.)</p><p></p><p class="bulletIndent1">In immunocompromised individuals, cellulitis can be due to a multitude of organisms including atypical bacteria, fungi, viruses, and parasites. If these individuals fail to respond to broad-spectrum antibiotic therapy, a dermatologic evaluation and skin biopsy can be beneficial. Nodular or ulcerative lesions should be biopsied early during the clinical course in highly immunocompromised individuals, especially for those who are septic or have rapidly progressive illness. Further discussion of skin infection in neutropenic individuals is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever", section on 'Skin and mucous membranes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate adherence</strong> – A repeat course of antimicrobial therapy and further instruction regarding elevation and other adjunctive therapies may be appropriate for patients with inadequate adherence to the treatment plan.</p><p></p><p class="headingAnchor" id="H365644463"><span class="h1">RECURRENT INFECTION</span><span class="headingEndMark"> — </span>Recurrent erysipelas and cellulitis are not uncommon occurrences. Recurrences have been reported to occur in 14 percent of cellulitis cases within one year and up to 45 percent of cases within three years, usually in the same location [<a href="#rid3">3,49,50</a>]. In one review of over 400,000 admissions for cellulitis, the readmission rate was 10 percent and most readmissions were due to recurrent cellulitis [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H4008532743"><span class="h2">Management of recurrent infection</span><span class="headingEndMark"> — </span>During the active stage of infection, management of recurrent episodes is the same as the approach for initial episodes (see <a class="local">'Acute cellulitis'</a> above). For individuals who have frequent or severe recurrences, prefilled prescriptions for treatment doses of antibiotics can be provided so that patients can self-initiate antibiotic therapy at the onset of symptoms while seeking immediate medical attention.</p><p class="headingAnchor" id="H3217687139"><span class="h2">Prevention of recurrences</span><span class="headingEndMark"> — </span>Potential tools for prevention of recurrent cellulitis include alleviation of predisposing conditions (such as use of compression therapy for management of edema), antibiotic prophylaxis, and <em>S. aureus</em> decolonization. These are discussed below.</p><p class="headingAnchor" id="H2825996725"><span class="h3">Alleviation of predisposing conditions</span><span class="headingEndMark"> — </span>Predisposing conditions should be identified and treated, if possible [<a href="#rid3">3</a>]. Examples of modifiable predisposing conditions include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Edema. Elevation of the affected area and diuretic therapy can help to alleviate edema. Compression therapy has been shown in studies to be highly effective for lymphedema and venous insufficiency and is discussed in detail below. (See <a class="local">'Compression therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Foot infections including intertrigo in the toe webs of the feet, tinea pedis, and onychomycosis. (See  <a class="medical medical_review" href="/z/d/html/115366.html" rel="external">"Intertrigo"</a> and  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections"</a> and  <a class="medical medical_review" href="/z/d/html/105222.html" rel="external">"Onychomycosis: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower extremity ulcers. (See  <a class="medical medical_review" href="/z/d/html/13680.html" rel="external">"Approach to the differential diagnosis of leg ulcers"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic skin conditions, such as eczema and psoriasis. (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obesity. (See  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression.</p><p></p><p class="headingAnchor" id="H1670365585"><span class="h3">Compression therapy</span><span class="headingEndMark"> — </span>For patients with recurrent episodes of cellulitis in the setting of chronic lower extremity venous insufficiency or lymphedema, compression therapy is an essential component of management that has been shown to be effective in reducing episodes of recurrent cellulitis [<a href="#rid52">52</a>].</p><p>In a randomized trial involving 84 patients with chronic lower extremity edema and ≥2 prior episodes of cellulitis, daily use of compression therapy reduced the rate of recurrent cellulitis compared with no compression therapy (15 versus 40 percent, respectively, at a median follow-up of six months; hazard ratio [HR] 0.23, 95% CI 0.09-0.59) [<a href="#rid52">52</a>]. The compression therapy was provided by specialized lymphedema physiotherapists and usually consisted of prescription knee-high stockings that included the foot and were worn throughout the day. The compression therapy was provided only when no active cellulitis was present, and no adverse events related to compression therapy were observed. Of note, the trial was stopped early for benefit, which tends to overestimate treatment efficacy.</p><p>Additional details regarding compression therapy in patients with chronic venous insufficiency and lymphedema are provided separately. (See  <a class="medical medical_review" href="/z/d/html/17013.html" rel="external">"Lower extremity lymphedema"</a> and  <a class="medical medical_review" href="/z/d/html/738.html" rel="external">"Clinical staging and conservative management of peripheral lymphedema"</a> and  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency"</a>.)</p><p class="headingAnchor" id="H1579485632"><span class="h3">Antibiotic prophylaxis for selected patients</span><span class="headingEndMark"> — </span>For patients who optimize predisposing conditions but still develop recurrent cellulitis in the same anatomic site, we suggest suppressive antibiotic therapy [<a href="#rid2">2</a>]. Although infrequent, there are scenarios (eg, complicated bacteremia in patients with a prosthetic device) when initiation of suppressive therapy after an initial bout of cellulitis may be warranted; consultation of clinicians with experience in these cases is suggested.</p><p>For suppressive therapy, we suggest one of the following antibiotic regimens:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with known or presumed beta-hemolytic streptococcal infection [<a href="#rid53">53-55</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">Penicillin V</a> (250 to 500 mg orally twice daily)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">Penicillin G benzathine</a> intramuscular (IM) injections (1.2 to 2.4 million units IM every four weeks; shorten interval to every two weeks if longer interval is not effective)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with known or presumed staphylococcal infection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">Cefadroxil</a> (500 mg orally twice daily)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">Cephalexin</a> (500 mg orally four times daily)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX; one double-strength tablet orally twice daily)</p><p></p><p><a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">Cefadroxil</a> and <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> have no activity against methicillin-resistant <em>S. aureus </em>(MRSA) and should only be used if recurrent methicillin-sensitive <em>S. aureus</em> (MSSA) infection is suspected.</p><p>For patients with reported beta-lactam allergies, we suggest referral to an allergist. If beta-lactam allergy is confirmed and TMP-SMX is not an option, we try <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily). We avoid <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (150 mg orally once daily) unless there are no other options due to risk of <em>C. difficile </em>infection [<a href="#rid56">56</a>].</p><p>Other than penicillin and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, minimal data exist to support the options listed above as suppressive agents. The optimal dosing for these antibiotics when used as prophylaxis is unknown and may be lower than the suggested doses. Titration to lower dosages over time may allow determination of the best dose for individual patients.</p><p>Serologic testing for beta-hemolytic streptococci may be a useful diagnostic tool to help guide the choice of suppressive antibiotic therapy. Such tests include the anti-streptolysin-O reaction and the anti-deoxyribonuclease B test (anti-DNAse B). Further information regarding serologic testing for beta-hemolytic streptococci is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p>Support for suppressive antibiotic therapy for prevention of recurrent cellulitis comes from multiple trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial that included 274 patients with two or more episodes of lower extremity cellulitis, penicillin (250 mg orally twice daily) nearly halved the risk of recurrence during 12 months of prophylaxis (HR 0.55, 95% CI 0.35 to 0.86), but the protective effect diminished rapidly after the prophylaxis period ended [<a href="#rid53">53</a>]. A lower likelihood of response was observed among patients with a body mass index ≥33 kg/m<sup>2</sup>, multiple previous episodes of cellulitis, or lower extremity edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two separate meta-analyses of five trials totalling over 500 patients with recurrent cellulitis concluded that prophylactic antibiotics substantially reduce the risk of subsequent cellulitis (relative risk [RR] 0.46, 95% CI 0.26-0.79, and RR 0.31, 95% CI 0.13 to 0.72, respectively) [<a href="#rid57">57,58</a>]. Findings from two of the included studies also demonstrated that antibiotic prophylaxis is cost-effective [<a href="#rid55">55,59</a>].</p><p></p><p>In the trials and meta-analyses, no significant differences in adverse effects were found between the groups that received antibiotics and those that did not.</p><p>Suppressive therapy may be continued for several months to years with interval assessments for efficacy and tolerance. Patients in whom recurrent cellulitis occurs while on suppressive therapy should undergo re-evaluation of predisposing conditions and antimicrobial agents. (See <a class="local">'Prevention of recurrences'</a> above.)</p><p class="headingAnchor" id="H2304880307"><span class="h3">S. aureus decolonization</span><span class="headingEndMark"> — </span>For patients with suspected recurrent <em>S. aureus</em> infection, we suggest an attempt at <em>S. aureus</em> decolonization. Detailed discussion of <em>S. aureus </em>decolonization is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control", section on 'Decolonization'</a> and  <a class="medical medical_review" href="/z/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control"</a>.)</p><p class="headingAnchor" id="H2628497941"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110086.html" rel="external">"Society guideline links: Skin and soft tissue infections"</a>.)</p><p class="headingAnchor" id="H1307446157"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Patients with skin and soft tissue infection may present with cellulitis, erysipelas, or abscess. This topic addresses management of cellulitis and erysipelas in adults. The management of skin abscess is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/138447.html" rel="external">"Skin abscesses in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify conditions treated differently than cellulitis</strong>  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>"Red-flag" conditions</strong> – These warrant immediate hospitalization and often surgery. Examples include  (<a class="graphic graphic_table graphicRef143606" href="/z/d/graphic/143606.html" rel="external">table 6</a>):</p><p class="bulletIndent3"><span class="glyph">-</span>Toxic shock syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Necrotizing soft tissue infection (eg, necrotizing fasciitis, including Fournier's gangrene)</p><p class="bulletIndent3"><span class="glyph">-</span>Clostridial myonecrosis</p><p class="bulletIndent3"><span class="glyph">-</span>Pyomyositis</p><p class="bulletIndent3"><span class="glyph">-</span>Deep venous thrombosis (DVT)</p><p class="bulletIndent3"><span class="glyph">-</span>Compartment syndrome</p><p></p><p class="bulletIndent2">(See <a class="local">'"Red-flag" conditions that warrant hospitalization'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Specific exposures and anatomic sites</strong> <strong>–</strong> Some exposures or anatomic sites may require distinct antibiotic coverage, surgical intervention, or specific radiographic imaging: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Involvement of the hand, periorbital space, or neck</p><p class="bulletIndent3"><span class="glyph">-</span>Location over a joint (native or prosthetic), vascular graft, or other foreign body</p><p class="bulletIndent3"><span class="glyph">-</span>Infection of a diabetic foot ulcer, pressure ulcer, animal or human bite, puncture wound, or surgical wound</p><p class="bulletIndent3"><span class="glyph">-</span>Infection following exposure to water, soil, or recent travel</p><p></p><p class="bulletIndent2">(See <a class="local">'Wounds and exposures that warrant specific coverage'</a> above and <a class="local">'Anatomic site of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic selection for cellulitis in immunocompetent patients without severe sepsis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Determine risk for MRSA or adverse outcomes</strong> – Antibiotic selection depends on the risk for methicillin-resistant <em>S. aureus </em>(MRSA) or adverse outcomes. Features that increase those risks in this population include (see <a class="local">'Indications for MRSA coverage'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Systemic toxicity (eg, fever, tachycardia) </p><p class="bulletIndent3"><span class="glyph">-</span>Purulent wound drainage</p><p class="bulletIndent3"><span class="glyph">-</span>Known MRSA colonization or infection</p><p class="bulletIndent3"><span class="glyph">-</span>Injection drug use</p><p class="bulletIndent3"><span class="glyph">-</span>Immunocompromise</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic regimens</strong></p><p></p><p class="bulletIndent2">For immunocompetent patients with one of the above features, we suggest a regimen that covers beta-hemolytic streptococci, methicillin-sensitive <em>S. aureus</em> (MSSA), and MRSA  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'With an indication for MRSA coverage'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Oral – <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a></p><p class="bulletIndent3"><span class="glyph">-</span>Intravenous (IV) – <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a></p><p class="bulletIndent3"><span class="glyph">-</span>Other risk factors  (<a class="graphic graphic_table graphicRef53504" href="/z/d/graphic/53504.html" rel="external">table 2</a>) may not be as strongly associated with MRSA infection so we individualize the decision for MRSA coverage in such cases.</p><p></p><p class="bulletIndent2">For immunocompetent patients without the above features, we suggest a narrower regimen with coverage for beta-hemolytic streptococci and MSSA  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Without an indication for MRSA coverage'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Oral – <a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">Dicloxacillin</a>, flucloxacillin, <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a>, or <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">cefadroxil</a></p><p class="bulletIndent3"><span class="glyph">-</span>IV – <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">Cefazolin</a>, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>, <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, or flucloxacillin</p><p></p><p class="bulletIndent2">Intravenous therapy is warranted for patients with systemic toxicity (eg, fever, tachycardia), rapidly progressive or extensive erythema, or inability to absorb oral therapy. (See <a class="local">'Indications for parenteral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic regimens for cellulitis in patients with severe sepsis or an immunocompromising condition</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with severe sepsis (eg, evidence of tissue hypoperfusion or organ dysfunction) or high-risk neutropenia  (<a class="graphic graphic_table graphicRef67027" href="/z/d/graphic/67027.html" rel="external">table 5</a>), we suggest initial therapy with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This regimen provides broad coverage against MRSA, methicillin-sensitive <em>S. aureus </em>(MSSA), beta-hemolytic streptococci, and gram-negative organisms for patients at highest risk for poor outcomes. (See <a class="local">'Patients with severe sepsis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with other immunocompromising conditions (and without severe sepsis), we often use the same regimens as for immunocompetent patients. The decision to cover additional pathogens associated with specific conditions should be individualized  (<a class="graphic graphic_table graphicRef143607" href="/z/d/graphic/143607.html" rel="external">table 1</a>). (See <a class="local">'Immunocompromised patients without severe sepsis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic regimens for erysipelas</strong> – For patients with unambiguous erysipelas (eg, bright red erythema with distinct raised borders), we suggest antibiotics that primarily target streptococci (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1">Oral options include <a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">penicillin V</a> potassium, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a>, and <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">cefadroxil</a>. Parenteral options include <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>, and flucloxacillin. (See <a class="local">'Treatment of erysipelas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of antibiotic therapy</strong> – We suggest five to six days of therapy rather than longer durations (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, extended regimens (ie, up to 14 days) may be appropriate for severe or slowly responding cellulitis. Parenteral antibiotics should be switched to an oral option once clinical improvement has occurred. (See <a class="local">'Duration of antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapy</strong> – We instruct patients with cellulitis of the limb to elevate it to allow drainage of edema and hasten improvement. </p><p></p><p class="bulletIndent1">Areas of skin breakdown are potential points of entry that should be identified and managed. Common points of entry include intertrigo in the toe webs, tinea pedis, onychomycosis, lower extremity ulcers, atopic dermatitis, and psoriasis. (See <a class="local">'Adjunctive treatments'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expected response</strong> – Symptomatic improvement typically occurs within 24 to 48 hours, although visible improvement of skin manifestations can take 72 hours or longer. (See <a class="local">'Monitoring response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory infection</strong> – Significant progression of erythema or continued systemic symptoms should prompt a search for possible reasons for treatment failure. Considerations include deeper infection, inadequate antibiotic penetration (eg, due to edema), or incorrect diagnosis. (See <a class="local">'Refractory infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent infection</strong> – During the active stage of infection, management of recurrent episodes is the same as the approach for initial episodes.</p><p></p><p class="bulletIndent1">There are multiple tools to prevent recurrences (see <a class="local">'Recurrent infection'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treating points of entry </strong>(eg, intertrigo, chronic skin conditions). (See <a class="local">'Alleviation of predisposing conditions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Managing predisposing conditions</strong> – For patients with lymphedema or venous insufficiency, we suggest compression therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Compression therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic prophylaxis for select patients</strong> – For patients who optimize predisposing conditions but still have recurrent cellulitis in the same anatomic site, we suggest prophylactic antibiotics (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For most patients, our preferred regimen is <a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">penicillin V</a> (250 to 500 mg orally twice daily). (See <a class="local">'Antibiotic prophylaxis for selected patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>S. aureus </em></strong><strong>decolonization</strong> – For patients with suspected recurrent <em>S. aureus</em> infection, some experts attempt decolonization. (See  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control", section on 'Decolonization'</a> and  <a class="medical medical_review" href="/z/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control"</a>.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></li><li><a class="nounderline abstract_t">Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA 2016; 316:325.</a></li><li><a class="nounderline abstract_t">Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 2018; 36:1443.</a></li><li class="breakAll">The Medical Letter. Drugs for MRSA Skin and Soft-Tissue Infections, May 12, 2014. https://secure.medicalletter.org/article-share?a=1442b&amp;p=tml&amp;title=Drugs%20for%20MRSA%20Skin%20and%20Soft-Tissue%20Infections&amp;cannotaccesstitle=1 (Accessed on May 22, 2018).</li><li><a class="nounderline abstract_t">Yamaguchi H, Kobayashi H, Nagasaki K. Abdominal Wall Cellulitis in Acute Abdomen. Intern Med 2020; 59:595.</a></li><li><a class="nounderline abstract_t">Beerle C, Gelpke H, Breitenstein S, Staerkle RF. Complicated acute appendicitis presenting as a rapidly progressive soft tissue infection of the abdominal wall: a case report. J Med Case Rep 2016; 10:331.</a></li><li><a class="nounderline abstract_t">Tanaka R, Kameyama H, Chida T, et al. Severe cellulitis and abdominal wall emphysema following laparoscopic colonic surgery: A case report. Asian J Endosc Surg 2015; 8:193.</a></li><li><a class="nounderline abstract_t">Bischoff K, López C, Shaffer K, Schwaitzberg S. Colorectal Adenocarcinoma Presenting as Abdominal Wall Cellulitis. Radiol Case Rep 2008; 3:204.</a></li><li><a class="nounderline abstract_t">Maier A, Boieriu L. Abdominal wall non-clostridian gas cellulitis: a rare complication of a colostoma. Chirurgia (Bucur) 2014; 109:697.</a></li><li><a class="nounderline abstract_t">Hakeem A, Shanmugam V, Badrinath K, et al. Delay in diagnosis and lessons learnt from a case of abdominal wall abscess caused by fishbone perforation. Ann R Coll Surg Engl 2015; 97:e39.</a></li><li><a class="nounderline abstract_t">Maginot TJ, Cascade PN. Abdominal wall cellulitis and sepsis secondary to percutaneous cecostomy. Cardiovasc Intervent Radiol 1993; 16:328.</a></li><li><a class="nounderline abstract_t">Disa JJ, Goldberg NH, Carlton JM, et al. Restoring abdominal wall integrity in contaminated tissue-deficient wounds using autologous fascia grafts. Plast Reconstr Surg 1998; 101:979.</a></li><li><a class="nounderline abstract_t">Al-Hendal A, Al-Masri W, Al-Mishaan M, Alexander S. Abscess of the abdominal wall resulting from perforated ascending colon cancer. Gulf J Oncolog 2009; :60.</a></li><li><a class="nounderline abstract_t">Tollens T, Speybrouck S, Devroe K, et al. Comparison of Recurrence Rates in Obese and Non-Obese Patients Undergoing Ventral Hernia Repair with Lighter-Weight, Partially Absorbable Mesh. Surg Technol Int 2011; 21:140.</a></li><li><a class="nounderline abstract_t">Latifi R, Gogna S. Surgery for Complex Abdominal Wall Defects: Update of a Nine-Step Treatment Strategy. Surg Technol Int 2022; 40.</a></li><li><a class="nounderline abstract_t">Ng K, Goddard K. Extremely Late-Onset Deep Infection Post Inguinal Hernia Repair After Panendoscopy. Cureus 2022; 14:e22169.</a></li><li><a class="nounderline abstract_t">Thorsteinsdottir B, Tleyjeh IM, Baddour LM. Abdominal wall cellulitis in the morbidly obese. Scand J Infect Dis 2005; 37:605.</a></li><li><a class="nounderline abstract_t">Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother 2014; 58:3799.</a></li><li><a class="nounderline abstract_t">Zahar JR, Timsit JF, Garrouste-Orgeas M, et al. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med 2011; 39:1886.</a></li><li><a class="nounderline abstract_t">Moran GJ, Krishnadasan A, Mower WR, et al. Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial. JAMA 2017; 317:2088.</a></li><li><a class="nounderline abstract_t">Pallin DJ, Binder WD, Allen MB, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis 2013; 56:1754.</a></li><li><a class="nounderline abstract_t">Cross ELA, Jordan H, Godfrey R, et al. Route and duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analysis of the effectiveness and harms of antibiotic treatment. J Infect 2020; 81:521.</a></li><li><a class="nounderline abstract_t">Dellsperger S, Kramer S, Stoller M, et al. Early Switch From Intravenous to Oral Antibiotics in Skin and Soft Tissue Infections: An Algorithm-Based Prospective Multicenter Pilot Trial. Open Forum Infect Dis 2022; 9:ofac197.</a></li><li><a class="nounderline abstract_t">Miller LG, Daum RS, Creech CB, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015; 372:1093.</a></li><li><a class="nounderline abstract_t">Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med 2017; 376:2545.</a></li><li><a class="nounderline abstract_t">Li Y, Xu W. Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis. Biosci Rep 2018; 38.</a></li><li><a class="nounderline abstract_t">Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2016; :CD008056.</a></li><li><a class="nounderline abstract_t">Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.</a></li><li><a class="nounderline abstract_t">Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.</a></li><li><a class="nounderline abstract_t">Lewis JS 2nd, Lepak AJ, Thompson GR 3rd, et al. Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections. Antimicrob Agents Chemother 2014; 58:1327.</a></li><li class="breakAll">U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf (Accessed on March 29, 2022).</li><li class="breakAll">Centers for Disease Control and Prevention. Healthcare-associated infections - Community Interface (HAIC): Emerging Infections Program (EIP) network report. Invasive Staphylococcus aureus, 2017. https://www.cdc.gov/hai/eip/pdf/2017-MRSA-Report-P.pdf (Accessed on May 04, 2022).</li><li class="breakAll">Australian Commission on Safety and Quality in Health Care. AURA 2021: Fourth Australian report on antimicrobial use and resistance in human health. https://www.safetyandquality.gov.au/publications-and-resources/resource-library/aura-2021-fourth-australian-report-antimicrobial-use-and-resistance-human-health (Accessed on July 05, 2022).</li><li><a class="nounderline abstract_t">Facinelli B, Spinaci C, Magi G, et al. Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci. Lancet 2001; 358:30.</a></li><li><a class="nounderline abstract_t">Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669.</a></li><li><a class="nounderline abstract_t">Lee RA, Centor RM, Humphrey LL, et al. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Ann Intern Med 2021; 174:822.</a></li><li><a class="nounderline abstract_t">Cranendonk DR, Opmeer BC, van Agtmael MA, et al. Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomized, double-blind, placebo-controlled, non-inferiority trial. Clin Microbiol Infect 2020; 26:606.</a></li><li><a class="nounderline abstract_t">Bojesen S, Midttun M, Wiese L. Compression bandaging does not compromise peripheral microcirculation in patients with cellulitis of the lower leg. Eur J Dermatol 2019; 29:396.</a></li><li><a class="nounderline abstract_t">Eder S, Stücker M, Läuchli S, Dissemond J. [Is compression therapy contraindicated for lower leg erysipelas? : Results of a retrospective analysis]. Hautarzt 2021; 72:34.</a></li><li><a class="nounderline abstract_t">Dall L, Peterson S, Simmons T, Dall A. Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy. Cutis 2005; 75:177.</a></li><li><a class="nounderline abstract_t">Davis JS, Mackrow C, Binks P, et al. A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb. Clin Microbiol Infect 2017; 23:242.</a></li><li><a class="nounderline abstract_t">Bergkvist PI, Sjöbeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis 1997; 29:377.</a></li><li><a class="nounderline abstract_t">Bruun T, Oppegaard O, Kittang BR, et al. Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study. Open Forum Infect Dis 2016; 3:ofv181.</a></li><li><a class="nounderline abstract_t">Bruun T, Oppegaard O, Hufthammer KO, et al. Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors. Clin Infect Dis 2016; 63:1034.</a></li><li><a class="nounderline abstract_t">Barras M, Legg A. Drug dosing in obese adults. Aust Prescr 2017; 40:189.</a></li><li><a class="nounderline abstract_t">Li DG, Xia FD, Khosravi H, et al. Outcomes of Early Dermatology Consultation for Inpatients Diagnosed With Cellulitis. JAMA Dermatol 2018; 154:537.</a></li><li><a class="nounderline abstract_t">Ko LN, Garza-Mayers AC, St John J, et al. Effect of Dermatology Consultation on Outcomes for Patients With Presumed Cellulitis: A Randomized Clinical Trial. JAMA Dermatol 2018; 154:529.</a></li><li><a class="nounderline abstract_t">McNamara DR, Tleyjeh IM, Berbari EF, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007; 167:709.</a></li><li><a class="nounderline abstract_t">Jorup-Rönström C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987; 15:105.</a></li><li><a class="nounderline abstract_t">Fisher JM, Feng JY, Tan SY, Mostaghimi A. Analysis of Readmissions Following Hospitalization for Cellulitis in the United States. JAMA Dermatol 2019; 155:720.</a></li><li><a class="nounderline abstract_t">Webb E, Neeman T, Bowden FJ, et al. Compression Therapy to Prevent Recurrent Cellulitis of the Leg. N Engl J Med 2020; 383:630.</a></li><li><a class="nounderline abstract_t">Thomas KS, Crook AM, Nunn AJ, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med 2013; 368:1695.</a></li><li><a class="nounderline abstract_t">van Zuuren EJ, Fedorowicz Z, Alper B, Mitsuma SF. Penicillin to prevent recurrent leg cellulitis: a critical appraisal. Br J Dermatol 2014; 171:1300.</a></li><li><a class="nounderline abstract_t">UK Dermatology Clinical Trials Network’s PATCH Trial Team, Thomas K, Crook A, et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial. Br J Dermatol 2012; 166:169.</a></li><li><a class="nounderline abstract_t">Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988; 260:2682.</a></li><li><a class="nounderline abstract_t">Oh CC, Ko HC, Lee HY, et al. Antibiotic prophylaxis for preventing recurrent cellulitis: a systematic review and meta-analysis. J Infect 2014; 69:26.</a></li><li><a class="nounderline abstract_t">Dalal A, Eskin-Schwartz M, Mimouni D, et al. Interventions for the prevention of recurrent erysipelas and cellulitis. Cochrane Database Syst Rev 2017; 6:CD009758.</a></li><li><a class="nounderline abstract_t">Mason JM, Thomas KS, Crook AM, et al. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I &amp; II trials. PLoS One 2014; 9:e82694.</a></li></ol></div><div id="topicVersionRevision">Topic 110530 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434444" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cellulitis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29461916" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29461916" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31619596" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Abdominal Wall Cellulitis in Acute Abdomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27906036" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Complicated acute appendicitis presenting as a rapidly progressive soft tissue infection of the abdominal wall: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25913586" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe cellulitis and abdominal wall emphysema following laparoscopic colonic surgery: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27303548" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Colorectal Adenocarcinoma Presenting as Abdominal Wall Cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25375062" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Abdominal wall non-clostridian gas cellulitis: a rare complication of a colostoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26263825" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Delay in diagnosis and lessons learnt from a case of abdominal wall abscess caused by fishbone perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8269434" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Abdominal wall cellulitis and sepsis secondary to percutaneous cecostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9514330" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Restoring abdominal wall integrity in contaminated tissue-deficient wounds using autologous fascia grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20084789" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Abscess of the abdominal wall resulting from perforated ascending colon cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504983" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of Recurrence Rates in Obese and Non-Obese Patients Undergoing Ventral Hernia Repair with Lighter-Weight, Partially Absorbable Mesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35313000" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Surgery for Complex Abdominal Wall Defects: Update of a Nine-Step Treatment Strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35308762" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Extremely Late-Onset Deep Infection Post Inguinal Hernia Repair After Panendoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16138431" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Abdominal wall cellulitis in the morbidly obese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24752269" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21516036" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28535235" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23457080" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32745638" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Route and duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analysis of the effectiveness and harms of antibiotic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35794940" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early Switch From Intravenous to Oral Antibiotics in Skin and Soft Tissue Infections: An Algorithm-Based Prospective Multicenter Pilot Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25785967" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657870" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29229674" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26758498" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Linezolid versus vancomycin for skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015695" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917519" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323478" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323478" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323478" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323478" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454374" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302637" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33819054" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31618678" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomized, double-blind, placebo-controlled, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31512577" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Compression bandaging does not compromise peripheral microcirculation in patients with cellulitis of the lower leg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32930854" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : [Is compression therapy contraindicated for lower leg erysipelas? : Results of a retrospective analysis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15839362" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28274772" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360253" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26734653" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27402819" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29109603" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Drug dosing in obese adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29453874" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Outcomes of Early Dermatology Consultation for Inpatients Diagnosed With Cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29453872" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of Dermatology Consultation on Outcomes for Patients With Presumed Cellulitis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420430" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A predictive model of recurrent lower extremity cellulitis in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3110071" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Recurrent erysipelas: predisposing factors and costs of prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30810708" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Analysis of Readmissions Following Hospitalization for Cellulitis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32786188" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Compression Therapy to Prevent Recurrent Cellulitis of the Leg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635049" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Penicillin to prevent recurrent leg cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25523263" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Penicillin to prevent recurrent leg cellulitis: a critical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21910701" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3184334" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24576824" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antibiotic prophylaxis for preventing recurrent cellulitis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28631307" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Interventions for the prevention of recurrent erysipelas and cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24551029" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I&amp;II trials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
